Results 151 to 160 of about 47,533 (300)

Docetaxel‐Induced Immune Activation Shows Antitumor Synergy With the Tumor‐Targeted CD40 Agonist KK2269

Cancer Science, EarlyView.
CD40 agonists have demonstrated proof‐of‐concept for converting an immunologically cold tumor into a hot tumor in preclinical studies; however, clinically, they have shown limited antitumor efficacy as monotherapy. We tested a tumor‐targeted CD40 agonist, KK2269 (a bispecific antibody that binds to CD40 and EpCAM), in combination with various ...
Yuta Tezuka, Kyoko Kawasaki, Yoshiki Sumitomo, Masato Saito, Akari Yao, Munetoshi Ando   +5 more
wiley   +1 more source

An evaluation of the efficacy of adenovirus-mediated gene therapy with p53 for the treatment of cancer [PDF]

, 2015
Cancer is the second leading cause of mortality in the United States today, and equally prevalent throughout the world. Traditional treatments such as chemotherapy and radiotherapy have thus far proven unable to treat the disease with high efficacy, with
Liepart IV, George Hampson
core   +1 more source

Neutrophil‐Macrophage Interactions Shape Inflammatory Macrophage Remodeling in Gastric Cancer During Chemo‐Immunotherapy

Cancer Science, EarlyView.
PD‐1 blockade combined with chemotherapy induces MHC‐II+ inflammatory neutrophils in gastric cancer, which engage in dynamic crosstalk with macrophages to remodel the tumor microenvironment toward a pro‐inflammatory state, thereby amplifying antitumor immune responses.
Keita H. Nagaoka, Hiroki Yamashita, Chiaki Mashima, Guoqiang Zhang, Hitoshi Saito, Tatsunori Minamide, Takuya Nakatsuru, Ryo Kamata, Shunsuke A. Sakai, Gaku Yamamoto, Tomoko Y. Morita, Kazuki Nakai, Yumi Hakozaki, Kumi Kinoshita, Yui Takahashi, Izuma Nakayama, Akihito Kawazoe, Sai M. Pulukuri, Yuko Ishii, Hiroshi Haeno, Yukie Kashima, Kohei Shitara, Tomonori Yano, Takeshi Saito, Akihiro Ohashi   +24 more
wiley   +1 more source

Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. [PDF]

, 2020
PurposeThe goal of the present study was to determine the efficacy of temozolomide (TEM) and pazopanib (PAZ) combined with FOLFOX (oxaliplatin, leucovorin and 5-fluorouracil) on a colorectal cancer patient-derived orthotopic xenograft (PDOX) mouse model ...
Bouvet, Michael, Clary, Bryan, Han, Qinghong, Hoffman, Robert M, Singh, Shree Ram, Sun, Yu, Tan, Yuying, Ye, Jianxin, Zhao, Ming, Zhu, Guangwei   +9 more
core  

Aspartate Transporter SLC1A3 Promotes Colorectal Cancer via MDM2‐p53 Pathway and M2 Macrophage Polarization

Cancer Science, EarlyView.
SLC1A3 promotes colorectal cancer progression by transporting extracellular aspartate into tumor cells, thereby activating the PKC/MDM2/p53 pathway to enhance proliferation. Reduced extracellular aspartate, combined with p53‐dependent suppression of CSF2 and IL17C, drives M2 macrophage polarization via immune modulation, macrophage recruitment, and M2 ...
Chao Deng, You Zhou, Sijie Song, Hongtao Liu, Siqi Liao, Li Zhou, Siyuan Chen, Zhihang Zhou, Song He, Bingrong Liu   +9 more
wiley   +1 more source

Persistent in vitro nociceptor hyperexcitability and axonal retraction produced by repeated paclitaxel doses

The FEBS Journal, EarlyView.
Repeated paclitaxel exposure causes long‐lasting nociceptor hyperexcitability and axonal retraction in adult sensory neurons. Using a long‐term primary nociceptor culture, we show that hyperexcitability is mediated by sequential upregulation of NaV1.8, TRPV1, TRPA1, and TRPM8 channels.
Angela Lamberti, Victor Moreno Lozano, Asia Fernández‐Carvajal, Antonio Ferrer‐Montiel   +3 more
wiley   +1 more source

Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin [PDF]

, 2017
Ulrich‐Axel Bommer, Kara L. Vine, Prianka Puri, Martin Engel, Lisa Belfiore, Karen Fildes, Marijka Batterham, Alistair Lochhead, Morteza Aghmesheh   +8 more
openalex   +1 more source

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad, YuZhu Jin, Kai Luo, He Bai, Xudong Zhang, Xu Sun, Zahoor Maheen, Ali Tanveer, Saeed Muddasar Muhammad, Jialin Qu, Guixin Zhang   +10 more
wiley   +1 more source

DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer

Oncogenesis
Oxaliplatin is effective against colorectal cancer (CRC), but resistance hampers treatment. We found upregulated Dickkopf-1 (DKK1, a secreted protein) in oxaliplatin-resistant (OR) CRC cell lines and DKK1 levels increased by more than 2-fold in ...
Chi-Che Hsieh, Ting-Wei Li, Chun-Chun Li, Shang-Hung Chen, You-Lin Wei, Nai-Jung Chiang, Che-Hung Shen   +6 more
doaj   +1 more source

Adherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro‐inflammatory tumor microenvironment in esophageal adenocarcinoma

International Journal of Cancer, Volume 159, Issue 2, Page 501-515, 15 July 2026.
What's new? Esophageal adenocarcinoma (EAC) is an aggressive cancer with poor survival and variable response to perioperative chemotherapy. Although histopathological features correlate with outcomes, the relationship specifically between adherens junction (AJ) protein expression and treatment response in EAC remains uncertain.
Bastian Grothey, Heike Löser, Tillmann Bedau, Wolfgang Schröder, Christiane J. Bruns, Thomas Zander, Max Krämer, Reinhard Büttner, Alexander Quaas   +8 more
wiley   +1 more source